ATE393221T1 - Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen - Google Patents
Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungenInfo
- Publication number
- ATE393221T1 ATE393221T1 AT00992550T AT00992550T ATE393221T1 AT E393221 T1 ATE393221 T1 AT E393221T1 AT 00992550 T AT00992550 T AT 00992550T AT 00992550 T AT00992550 T AT 00992550T AT E393221 T1 ATE393221 T1 AT E393221T1
- Authority
- AT
- Austria
- Prior art keywords
- rrnas
- directed against
- antisense oligonucleotides
- against bacterial
- oligonucleotides directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16815099P | 1999-11-29 | 1999-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE393221T1 true ATE393221T1 (de) | 2008-05-15 |
Family
ID=22610334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00992550T ATE393221T1 (de) | 1999-11-29 | 2000-11-29 | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
Country Status (9)
Country | Link |
---|---|
US (2) | US6677153B2 (de) |
EP (1) | EP1238071B1 (de) |
JP (1) | JP2003516151A (de) |
KR (1) | KR20020064915A (de) |
AT (1) | ATE393221T1 (de) |
AU (1) | AU783874B2 (de) |
CA (1) | CA2392685C (de) |
DE (1) | DE60038695T2 (de) |
WO (1) | WO2001042457A2 (de) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516151A (ja) * | 1999-11-29 | 2003-05-13 | エイブイアイ バイオファーマ, インコーポレイテッド | 細菌16Sおよび23SrRNAに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用 |
KR20020097241A (ko) | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
RU2329305C2 (ru) * | 2001-03-01 | 2008-07-20 | Дзе Джонс Хопкинс Юниверсити | Количественный анализ, позволяющий одновременно обнаруживать и идентифицировать бактериальные инфекции |
EP1443109B1 (de) * | 2001-10-15 | 2010-02-24 | Nissin Foods Holdings Co., Ltd. | Primer und verfahren zum nachweis von bakterien |
GB0126415D0 (en) * | 2001-11-02 | 2002-01-02 | Univ Warwick | Enzymes and enzyme inhibition |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
ATE426575T1 (de) | 2003-01-07 | 2009-04-15 | Univ Ramot | Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben |
JP2004313181A (ja) | 2003-04-02 | 2004-11-11 | Canon Inc | 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法 |
US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US7750142B2 (en) * | 2003-04-28 | 2010-07-06 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
ES2500921T3 (es) | 2003-04-29 | 2014-10-01 | Sarepta Therapeutics, Inc. | Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células |
CA2530927A1 (en) | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
WO2005013905A2 (en) * | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
EP1663199B1 (de) * | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen |
WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
US8007847B2 (en) * | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
WO2005072527A2 (en) * | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
US7402574B2 (en) * | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
EP1766012B1 (de) | 2004-07-02 | 2011-05-25 | AVI BioPharma, Inc. | Antisinn antibakterielle verfahren und verbindungen |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
US8568637B2 (en) | 2004-08-02 | 2013-10-29 | Ramot At Tel-Aviv University Ltd. | Method of forming a fiber made of peptide nanostructures |
EP1793816B1 (de) | 2004-08-19 | 2012-01-04 | Tel Aviv University Future Technology Development L.P. | Zusammensetzungen zur behandlung von amyloid-assoziierten erkrankungen |
WO2006027780A2 (en) * | 2004-09-08 | 2006-03-16 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US7300631B2 (en) * | 2005-05-02 | 2007-11-27 | Bioscale, Inc. | Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles |
US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US20060292575A1 (en) * | 2005-06-24 | 2006-12-28 | Asiagen Corporation | Novel method for diagnosing pathogens of sexually transmitted diseases |
US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
EP1937278B1 (de) * | 2005-09-08 | 2012-07-25 | AVI BioPharma, Inc. | Antivirale antisense-verbindung und verfahren zur behandlung von picornavirus-infektion |
JP4827483B2 (ja) * | 2005-10-04 | 2011-11-30 | キヤノン株式会社 | 核酸試料処理装置 |
WO2007043048A2 (en) * | 2005-10-11 | 2007-04-19 | Ramot At Tel Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
CA2644262C (en) * | 2006-03-07 | 2016-01-05 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
ES2396453T3 (es) * | 2006-04-24 | 2013-02-21 | Sigma Alimentos, S.A. De C.V. | Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real |
DK2735568T3 (da) * | 2006-05-10 | 2017-11-13 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske bindinger mellem underenheder |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
WO2008064304A2 (en) * | 2006-11-22 | 2008-05-29 | Trana Discovery, Inc. | Compositions and methods for the identification of inhibitors of protein synthesis |
US20090035767A1 (en) * | 2006-11-28 | 2009-02-05 | Canon Kabushiki Kaisha | Primer for bacterium genome amplification reaction |
US20080173652A1 (en) * | 2007-01-23 | 2008-07-24 | Bob Chou | Integral heat-resisting structure of a disposable drinking cup |
EP2121987B1 (de) | 2007-02-09 | 2012-06-13 | Northwestern University | Partikel zur erkennung intrazellulärer ziele |
DK2826863T3 (en) * | 2007-05-30 | 2017-12-04 | Univ Northwestern | NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS |
EP1997907A1 (de) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobakterien |
CN101855351A (zh) * | 2007-09-14 | 2010-10-06 | 特拉纳探索公司 | 鉴别反转录病毒感染抑制剂的组合物和方法 |
EP2253712B1 (de) * | 2008-03-03 | 2015-01-14 | Saitama Medical University | Verfahren zur erkennung eines entzündungserregers als verursacher von akuter atemwegsinfektion |
KR100966015B1 (ko) * | 2008-03-24 | 2010-06-24 | 이화여자대학교 산학협력단 | 식중독 병원균의 동시 검출용 프라이머 및 이의 용도 |
WO2010036795A2 (en) * | 2008-09-29 | 2010-04-01 | Trana Discovery, Inc. | Screening methods for identifying specific staphylococcus aureus inhibitors |
DK2365803T3 (en) * | 2008-11-24 | 2018-01-22 | Univ Northwestern | POLYVALENT RNA NANOPARTICLE COMPOSITIONS |
AU2009335740B2 (en) * | 2008-12-17 | 2016-04-21 | Sarepta Therapeutics, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2010081049A1 (en) * | 2009-01-08 | 2010-07-15 | Northwestern University | Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates |
AU2010237001B2 (en) | 2009-04-15 | 2016-07-07 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
EP2446057B1 (de) * | 2009-06-23 | 2014-11-19 | Gen-Probe Incorporated | Zusammensetzungen und verfahren für den nukleinsäurenachweis aus mollicutes |
WO2011019993A2 (en) * | 2009-08-14 | 2011-02-17 | Epicentre Technologies Corporation | METHODS, COMPOSITIONS, AND KITS FOR GENERATING rRNA-DEPLETED SAMPLES OR ISOLATING rRNA FROM SAMPLES |
DK2494075T3 (en) | 2009-10-30 | 2018-07-23 | Univ Northwestern | TABLE-MANAGED NANOCONJUGATES |
KR101944119B1 (ko) | 2009-11-13 | 2019-01-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법 |
CA2787156C (en) | 2010-01-19 | 2020-12-29 | Northwestern University | Synthetic nanostructures for delivery of oligonucleotides |
WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
JP2013530154A (ja) | 2010-05-28 | 2013-07-25 | サレプタ セラピューティクス, インコーポレイテッド | 修飾されたサブユニット間結合および/または末端基を有するオリゴヌクレオチドアナログ |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
EP2638161A1 (de) * | 2010-11-12 | 2013-09-18 | Sarepta Therapeutics, Inc. | Antibakterielle antisense-verbindungen und verfahren |
MX2013005413A (es) | 2010-11-15 | 2014-02-27 | Univ Ramot | Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides. |
JP2014526517A (ja) | 2011-09-14 | 2014-10-06 | ノースウェスタン ユニバーシティ | 血液脳関門を通過することができるナノ抱合体 |
JP6092226B2 (ja) | 2011-09-20 | 2017-03-08 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Gcgr発現のアンチセンス調整 |
BR112014006527A2 (pt) * | 2011-09-21 | 2017-03-28 | Syngenta Participations Ag | resistência patogênica |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
CN111808135A (zh) | 2011-11-18 | 2020-10-23 | 萨勒普塔医疗公司 | 功能改性的寡核苷酸及其亚单元 |
EP2812434B1 (de) * | 2012-02-09 | 2018-03-28 | Bavarian Nordic A/S | Agonisten und antagonisten des toll-like-rezeptors (tlr) 13 |
JP5800443B2 (ja) * | 2012-11-09 | 2015-10-28 | 株式会社村田製作所 | 二次電池、及び二次電池の充放電方法 |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
US11359249B2 (en) * | 2014-05-06 | 2022-06-14 | Is-Diagnostics Ltd | Microbial population analysis |
EP3508198A1 (de) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalente ausgabe von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen |
JP6741673B2 (ja) | 2014-10-06 | 2020-08-19 | イグジキュア, インコーポレーテッドExicure, Inc. | 抗tnf化合物 |
WO2016061398A1 (en) * | 2014-10-17 | 2016-04-21 | Fred Hutchinson Cancer Research Center | Methods, kits & compositions to assess helicobacter pylori infection |
KR20170078843A (ko) | 2014-11-21 | 2017-07-07 | 노오쓰웨스턴 유니버시티 | 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수 |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
US11142764B2 (en) | 2015-12-23 | 2021-10-12 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
ES2886270T3 (es) * | 2016-05-10 | 2021-12-16 | American Molecular Laboratories Inc | Métodos para caracterizar bacterias resistentes a fármacos a partir de muestras biológicas fijadas en formalina e incrustadas en parafina |
EP3652186A4 (de) | 2017-07-13 | 2021-03-31 | Northwestern University | Allgemeines und direktes verfahren zur herstellung von oligonukleotidfunktionalisierten metallorganischen gerüstnanopartikeln |
CN111328331A (zh) * | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | 用于将肠道中的抗生素抗性细菌去定植的组合物和方法 |
EP3728601A4 (de) * | 2018-01-17 | 2021-03-17 | Augmanity Nano Ltd | Satz von antipathogenen nukleinsäuren, zusammensetzungen und verwendungen davon |
WO2020210378A1 (en) * | 2019-04-08 | 2020-10-15 | University Of Massachusetts | Localization of payload delivery systems to tumor sites via beacon cell targeting |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5220014A (en) * | 1989-11-13 | 1993-06-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rrna specific oligonucleotides |
DE69033986T2 (de) * | 1989-12-20 | 2003-03-13 | Antivirals Inc | Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten |
US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
US5821052A (en) | 1992-04-16 | 1998-10-13 | University Of Medicine And Dentistry Of New Jersey | Control of the synthesis of proteins by anitisense RNA-tRNA complex |
US6060456A (en) | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
WO1998003533A1 (en) * | 1996-07-24 | 1998-01-29 | Oligos Etc. And Oligos Therapeutics, Inc. | Antisense oligonucleotides as antibacterial agents |
JP2001509167A (ja) * | 1997-01-24 | 2001-07-10 | エイブイアイ バイオファーマ,インコーポレイテッド | H.pylori感染を処置するための方法および結合体 |
GB2341390B (en) | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
US6204019B1 (en) | 1997-06-04 | 2001-03-20 | Smithkline Beecham Corporation | Sec A2 from Streptococcus pneumoniae |
US6610539B1 (en) | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
EP0894857A3 (de) | 1997-08-01 | 2001-09-26 | Smithkline Beecham Corporation | SecA Gen aus Streptococcus pneumoniae |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US6228579B1 (en) | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
JP2003516151A (ja) | 1999-11-29 | 2003-05-13 | エイブイアイ バイオファーマ, インコーポレイテッド | 細菌16Sおよび23SrRNAに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用 |
WO2001049775A2 (en) | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
-
2000
- 2000-11-29 JP JP2001544332A patent/JP2003516151A/ja active Pending
- 2000-11-29 WO PCT/US2000/042391 patent/WO2001042457A2/en active IP Right Grant
- 2000-11-29 AU AU45098/01A patent/AU783874B2/en not_active Expired
- 2000-11-29 KR KR1020027006894A patent/KR20020064915A/ko not_active Application Discontinuation
- 2000-11-29 US US09/726,774 patent/US6677153B2/en not_active Expired - Lifetime
- 2000-11-29 DE DE60038695T patent/DE60038695T2/de not_active Expired - Lifetime
- 2000-11-29 AT AT00992550T patent/ATE393221T1/de not_active IP Right Cessation
- 2000-11-29 CA CA2392685A patent/CA2392685C/en not_active Expired - Lifetime
- 2000-11-29 EP EP00992550A patent/EP1238071B1/de not_active Expired - Lifetime
-
2003
- 2003-11-21 US US10/719,633 patent/US7238675B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60038695D1 (de) | 2008-06-05 |
US20040137485A1 (en) | 2004-07-15 |
US20020082226A1 (en) | 2002-06-27 |
EP1238071B1 (de) | 2008-04-23 |
US6677153B2 (en) | 2004-01-13 |
CA2392685C (en) | 2011-02-22 |
US7238675B2 (en) | 2007-07-03 |
CA2392685A1 (en) | 2001-06-14 |
EP1238071A2 (de) | 2002-09-11 |
WO2001042457A2 (en) | 2001-06-14 |
JP2003516151A (ja) | 2003-05-13 |
AU4509801A (en) | 2001-06-18 |
DE60038695T2 (de) | 2009-05-28 |
WO2001042457A3 (en) | 2002-01-31 |
AU783874B2 (en) | 2005-12-15 |
KR20020064915A (ko) | 2002-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE393221T1 (de) | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen | |
DE60109589D1 (de) | Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne | |
ATE325614T1 (de) | Milchsäurebakterienkombination und deren verwendung zur behandlung und prävention von infektionen und entzündungen | |
WO2006013441A3 (en) | Use of probiotic bacteria for the preparation of topical compositions for skin protection | |
WO2007014372A3 (en) | Compositions and methods for treating bacteria | |
ATE207755T1 (de) | Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen | |
ATE427116T1 (de) | Behandlung von bakteriellen infektionen | |
EP1015011A4 (de) | Peptidnukleinsäuren mit antibakterieller aktivität | |
ATE293463T1 (de) | Zusammensetzung und verfahren zur entkeimung von luft | |
MXPA03007881A (es) | Bacterias productoras de acido lactico para tratar y prevenir la alergia. | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
GB9902555D0 (en) | Medicament | |
EP1362600A4 (de) | Pharmazeutische zusammensetzungen mit einem decoy und verfahren zu ihrer verwendung | |
IL162917A0 (en) | A lysin from bacteriophage and pharmaceutical compositions containing the same | |
DE60008895D1 (de) | Makrolid-antibiotika und behandlung von pasteurellosis | |
EE200000587A (et) | Uued 15-lülilised ketoasaliidid, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon kasutamiseks bakternakkuste ravis | |
DE69937615D1 (de) | Mittel zur Behandlung von Gewebe welches Wasser abweist und das Gewebe selbst | |
BR0315437A (pt) | Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos | |
EE200300064A (et) | Farmatseutiline kompositsioon C. pneumoniae pooltpõhjustatud infektsioonide raviks ja/või ennetamiseks, mahekompositsioon ja nende kasutamine | |
EP1019084A4 (de) | Neue antimikrobielle polypeptide und verfahren für ihre verwendung. | |
BR0111989A (pt) | Peptìdeos, composições e processos para o tratamento de burkholderia cepacia | |
PT1227827E (pt) | Bacterias acido-lacticas para o tratamento e/ou profilaxia da giardiase | |
ATE362765T1 (de) | Milchsäurebakterien mit anxiolytischer wirkung, und ihre verwendungen | |
MXPA02000504A (es) | Metodo de purificar agua, bacterias adecuadas para el metodo y uso de las mismas. | |
ATE291586T1 (de) | Humanes antibiotisches protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |